logo
PATH launches landmark AI study in Africa exploring LLMs' potential in health diagnoses

PATH launches landmark AI study in Africa exploring LLMs' potential in health diagnoses

Geek Wirea day ago
Penda Health clinicians Oscar Murebu (left) and Naomi Ndwiga review information in the clinic's electronic medical record, which includes an integrated AI consult tool for clinical decision support. (PATH Photo / Waithera Kamau)
PATH has launched the largest study of its kind in Africa, recruiting 9,000 participants to test whether artificial intelligence can help primary care clinicians make better diagnoses and treatment decisions in resource-limited settings.
The Seattle-based global health nonprofit is deploying large-language model (LLM) technology at clinics in Nairobi to analyze patient symptoms, health histories, provider notes and lab results, and then assist with diagnosis and treatment planning.
Bilal Mateen, PATH's first chief AI officer, is leading the organization's wide-ranging AI initiatives that include using tools to accelerate vaccine development and deploying chatbots to discuss sensitive health topics like HPV vaccination with teenage girls. Mateen is proceeding with both excitement and caution as he navigates what he calls 'potentially very risky technology' in vulnerable populations.
The medical AI-assistant study, conducted in partnership with the Kenya Paediatric Research Consortium, the University of Birmingham, and Nairobi clinic operator Penda Health, aims to provide the kind of rigorous evidence that has been missing from digital healthcare initiatives in low- and middle-income countries.
Bilal Mateen, chief of AI at PATH. (PATH Photo)
'This trial marks an important milestone for our health sector. AI has the potential to bridge health care gaps, particularly in underserved regions,' said Dr. Deborah Mlongo Barasa, Kenya's cabinet Secretary of Health, in a release announcing the study. 'We look forward to the insights it will generate to guide responsible and effective AI adoption.'
While organizations have pursued diagnostic assistance tools for years, most get stuck in pilot phases without proving their real-world value, Mateen said.
'Does this tool reduce the rate of treatment failures, people having to come back with unresolved symptoms, people being admitted to hospital as an emergency, people dying?' Mateen said. 'I don't know the answer yet.'
Results from the trial are expected by the end of the year.
PATH recently launched a second, smaller trial in Nigeria that features a toll-free hotline the provides responses to health inquiries using generative AI. The tool is called the Community Health Extension Worker Assistant (CHEWA) and is meant to serve healthcare workers who don't have access to the internet.
The study will run until providers log 3,000 patient encounters. The work is being done in partnership with Viamo, a Canadian social enterprise.
GeekWire recently spoke to Mateen about PATH's broader AI efforts. Here are some highlights.
Challenging misconceptions
Mateen calls out two misconceptions about AI and healthcare.
While AI could boost the efficiency and effectiveness of providers by using diagnostic assistants, that doesn't always equal to lower healthcare costs. Better-performance could identify more healthcare needs for lab tests, treatments, etc.
Though LLMs are typically trained on information from higher-income nations, AI tools don't necessarily need to be customized for local communities, depending on the use case. A patient with high blood pressure readings, for example, points to hypertension no matter where they live.
Faster, cheaper breakthroughs
PATH is testing whether Google's AI co-scientist can identify correlations in immune response and vaccine effectiveness that normally require multimillion-dollar trials to prove, potentially shortcutting research for new vaccines.
The nonprofit is also using AI to search scientific literature for 'unicorn biomarkers' — rare biological signals that could help fight deadly diseases including rotavirus, gastroenteritis and Respiratory Syncytial Virus.
AI on touchy subjects
Mateen is interested in chatbots taking the lead in uncomfortable conversations about sensitive issues such as vaccinating against human papilloma virus, for example, which is sexually transmitted and can cause cervical cancer.
It can be awkward discuss these serious issues with teenage girls and in some countries these topics are strictly taboo, said Mateen. 'We've discovered it's much easier to get that 14-year-old to speak to an empathetic chatbot, than it is a teacher or some other authority figure in their lives.'
Supporting regulation creation
PATH is hoping to land a grant to support the establishment of healthcare related AI-regulations in low- and middle-income countries.
AI-based technology poses potentially heightened risks for these populations, Mateen said, given their limited access to healthcare, minimal regulatory oversight in this area, and lack of recourse if the AI goes awry.
PATH has spent decades helping these nations strengthen regulations for vaccines, drugs and diagnostic testing, he said. 'As much as we want to be the pioneers delivering the next thing, we also recognize a responsibility for us to make sure that there is a mechanism by which us and others are held to account.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Hepatitis Testing Market Size to Reach USD 5.75 Billion by 2032 Driven by Rising Prevalence, Early Detection Demand, and Technological Advancements
Hepatitis Testing Market Size to Reach USD 5.75 Billion by 2032 Driven by Rising Prevalence, Early Detection Demand, and Technological Advancements

Yahoo

time24 minutes ago

  • Yahoo

Hepatitis Testing Market Size to Reach USD 5.75 Billion by 2032 Driven by Rising Prevalence, Early Detection Demand, and Technological Advancements

U.S. Hepatitis Testing Market to Hit USD 1.94 Billion by 2032, Robust Infrastructure and Growing Demand for Early Detection Tools Fuels Growth. Austin, July 18, 2025 (GLOBE NEWSWIRE) -- Hepatitis Testing Market Size & Growth Analysis: According to SNS Insider, the global Hepatitis Testing Market was valued at USD 3.53 billion in 2023 and is projected to reach USD 5.75 billion by 2032, growing at a CAGR of 5.62% during the forecast period 2024-2032. The global hepatitis testing market is growing significantly due to the increasing incidence of hepatitis B and C infections, growing awareness around early diagnosis, and government-driven screening programs. Further, technological improvements in serological and molecular testing have enhanced test sensitivity and turnaround times, contributing to market Your Free Sample Copy of the Hepatitis Testing Market Report Today: The U.S. accounted for a substantial portion of the global market, valued at USD 1.22 billion in 2023, and is projected to reach USD 1.94 billion by 2032. This dominance is attributed to the presence of major diagnostic players, high healthcare spending, and a robust testing infrastructure across hospitals and diagnostic laboratories. Market Overview The hepatitis testing market is growing owing to the increase in demand for accurate diagnostic products, especially with the increase in the number of global hepatitis infections. Public health organizations such as the WHO and CDC are promoting mass screening and early diagnosis policies, extending the scope and frequency of hepatitis testing across the globe. Multitarget detection has changed the testing landscape with respect to hepatitis viruses in recent years, especially due to advancements in immunoassay and PCR-based diagnostics that now allow simultaneous testing. Furthermore, growing trend towards integrated healthcare systems and government initiatives for reimbursement policies will encourage the adoption of diagnosis testing kits. Developed regions such as North America and Europe with well-established laboratory networks and insurance policies conducive to mass screening. At the same time, low and middle-income countries are fast catching up because of increased awareness and international healthcare partnerships. The rising interest in point-of-care testing and home-use testing products will also drive long-term market growth in the next ten years. Major Players Analysis Listed in this Report are: Abbott Laboratories (Architect Anti-HCV, Alinity HCV) Analytik Jena (AdiSelect HCV, AdiSelect HCV Real-Time PCR Kit) Autobio Diagnostics (HCV Antibody Test Kit, HEV Antibody Test Kit Bio-Mérieux (VIDAS Anti-HCV, VIDAS HEV) Danaher Corporation (Cepheid Xpert HCV, LumiraDx HCV Test) DiaSorin (LIAISON HCV, LIAISON HCV) Grifols SA (Procleix HCV Assay, Procleix HEV Assay) Hologic Inc. (Aptima HCV Assay, Aptima HEV Assay) MedMira Inc. (Reveal HCV Test, Reveal HEV Test) Ortho-Clinical Diagnostics (Vitros Anti-HCV Test, Vitros HEV Test) Qualpro Diagnostics (HCV Rapid Test, HEV Rapid Test) Roche Molecular Diagnostics (Cobas HCV Test, Cobas HEV Test Siemens Healthcare (ADVIA Centaur HCV, Dimension Vista HEV) Sysmex Corporation (Sysmex HCV Test, Sysmex HCV Test) Thermo Fisher Scientific (TaqMan HCV Test, HCV Viral Load Test) PerkinElmer (HCV Viral Load Test, HEV Serology Test) Qiagen (QIAstat-Dx Respiratory Panel, QIAamp Viral RNA Mini Kit) Becton, Dickinson and Company (BD) (BD MAX HCV Test, BD Veritor System forHCV) Myriad Genetics (Myriad RBM HCV Antibody Test, F. Hoffmann-La Roche LtD Hepatitis Testing Market Report Scope Report Attributes Details Market Size in 2023 US$ 3.53 billion Market Size by 2032 US$ 5.75 billion CAGR (2024–2032) 5.62% U.S. Market 2023 USD 1.22 billion U.S. Forecast by 2032 USD 1.94 billion Base Year 2023 Forecast Period 2024–2032 Key Regional Coverage North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) Segment Analysis By Test: In 2023, the highest proportion of the diagnostic methods preferred for hepatitis detection was blood tests, which is primarily due to their non-invasive nature, high accuracy, and suitability for the detection of various hepatitis virus types (HBV, HCV, HAV, HEV). These tests are commonly used in hospitals and labs to screen for disease on a large scale. Imaging Studies Imaging procedures (primarily not used for diagnostic purposes) include ultrasound sonography and elastography, which are developing at a remarkable pace, especially in the context of the management of chronic viral hepatitis in the assessment of liver fibrosis. By Technology: ELISA technology dominated due to its dependable nature, cost-effectiveness, and production of high-throughput tests. It is a widely used method for the detection of hepatitis antigens and antibodies in all healthcare facilities. The PCR is more and more widely used as it is unequaled in sensitivity and accuracy, competing with viral RNA/DNA potentially at its early stage for a precise diagnosis and follow-up of patients. By End User: The Hospitals and Diagnostic Laboratories market is the largest revenue-generating testing location on account of a wider reach (hence greater accessibility), presence of high-end laboratory equipment for testing, and alignment with insurance-based payment models. The Home care segment is augmenting in the domestic hepatitis devices market as the preference for self-testing, home diagnostic kits, and remote care health monitoring grows among chronic hepatitis patients and the at-risk population. By Product: Reagents and Kits (60% contribution in 2023): Reagents and kits will continue to be at the centre-stage of hepatitis testing protocols, given their high utilization, the need for re-testing, and product advancements that increase test accuracy and reliability. Instruments: Increasing technology for automating tests, particularly in PCR and immunoassay systems, is a key growth driver for instruments in centralized and decentralized diagnostic locations. For a Personalized Briefing with Our Industry Analysts, Connect Now: Hepatitis Testing Market Segmentation By Test Blood tests Imaging tests Liver Biopsy By Technology Enzyme-linked immunosorbent assay (ELISA) Rapid Diagnostic Test Polymerase Chain Reaction (PCR) Isothermal Nucleic Acid Amplification Technology (INAAT) Others By End Use Hospitals & Diagnostic Labs Blood Banks Others By Product Instruments Reagents & Kits Regional Analysis In 2023, North America accounted for the largest share of the hepatitis testing market, with 43% of the global share, mainly due to high awareness levels, organized screening programs, and investments in the development of advanced diagnostic technologies. The APAC market is projected to witness the highest growth rate during the forecast period, due to the rising prevalence of hepatitis B and C, developed healthcare infrastructure, and favorable government policies in countries such as China, India, and Southeast Asia. Recent Developments In November 2023, F. Hoffmann-La Roche Ltd Two automated serology tests for hepatitis E diagnosis (Elecsys Anti-HEV IgM, IgG). These tests are among those on WHO's Essential Diagnostics List. In April 2024, BioMérieux unveiled a fully automated hepatitis B and C multiplex assay on its VIDAS platform, which is expected to offer a faster turnaround time in clinical labs. In March 2024, Abbott Laboratories designed an enhanced version of its RealTime HCV test on the m2000 platform to further increase sensitivity for low viral load the Full Hepatitis Testing Market Report (Single-User License) Now: Table of Contents – Major Key Points 1. Introduction 2. Executive Summary 3. Research Methodology 4. Market Dynamics Impact Analysis 5. Statistical Insights and Trends Reporting 6. Competitive Landscape 7. Hepatitis Testing Market by Type 8. Hepatitis Testing Market by Technology 9. Hepatitis Testing Market by End Use 10. Hepatitis Testing Market by Product 11. Regional Analysis 12. Company Profiles 13. Use Cases and Best Practices 14. Conclusion About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: info@

Power shift: How CMU is helping shape America's energy evolution
Power shift: How CMU is helping shape America's energy evolution

Business Journals

time26 minutes ago

  • Business Journals

Power shift: How CMU is helping shape America's energy evolution

As AI models grow more powerful, their appetite for energy also increases, straining an aging and outdated grid and prompting urgent questions about infrastructure, security and access. From reimagining AI data centers to modernizing and securing the electric grid, Carnegie Mellon University researchers are working on practical solutions to pressing challenges in how the U.S. produces, moves and secures energy. The AI-energy connection While AI drives economic growth and scientific breakthroughs, it's also straining the energy infrastructure that is currently in place. The good news? AI can help solve that problem. expand Zico Kolter 'As work across Carnegie Mellon shows, AI has the potential to drastically improve our energy consumption by assisting in developing more efficient techniques for grid operation, building better materials for batteries, and potentially even truly revolutionizing energy by accelerating the development of technologies like nuclear fusion,' said Zico Kolter, head of the Machine Learning Department in CMU's School of Computer Science. 'These are all big bets, to be clear, and advancing science is never a sure thing, but AI at its best can be a unique enabler of so many beneficial downstream technologies.' Getting into the fast lane Carnegie Mellon is pioneering the use of AI to modernize the electric grid to meet current and future needs. 'Transmission moves power from the locations where it is produced to the locations where it is needed, and the U.S. urgently needs more capacity,' said M. Granger Morgan, the Hamerschlag University Professor of Engineering at CMU. 'The Department of Energy predicts the country will need to more than double high-voltage transmission capacity over the next several decades. At the same time the construction of new long-distance transmission has stalled. Breaking the logjam that often makes it impossible to build new transmission capacity without placing an unacceptable burden on consumers' electric bills is a major challenge.' expand M. Granger Morgan CMU researchers are developing 'AI fast lanes' — special lanes on the electricity "highway" just for clean energy projects that power AI and data centers. These fast lanes would let clean energy projects connect to the grid faster, ensure the electricity stays affordable and reliable, help protect the environment and make things fair for everyone. These innovations are crucial as the U.S. grid integrates more intermittent renewable sources like wind and solar. Securing the future As the grid becomes more digitized, security gaps widen — unless we address them. CMU's CyLab Security and Privacy Institute and Electrical and Computer Engineering department in the College of Engineering are working to stay ahead of the threat curve, using AI to anticipate and neutralize cyberattacks before they cause widespread disruption. 'AI-driven energy expansion is a prime opportunity to harden our infrastructure against cyber threats,' said Audrey Kurth Cronin, director of the Carnegie Mellon Institute for Strategy and Technology. 'Upgrading energy infrastructure for AI offers a once-in-a-generation opportunity to replace vulnerable legacy systems with inherently more defensible technologies.' CMU researchers Lujo Bauer, Larry Pileggi and Vyas Sekar are calling on the research and policy communities to develop more comprehensive and accurate grid evaluation frameworks and datasets, and for updating threat models and grid resiliency requirements to match cyber attackers' realistic capabilities. As part of their research, they interviewed 18 grid security specialists and analyzed four major threats, from overloading smart devices to taking over entire power plants. They found wide disagreement on how likely or dangerous these threats are. 'Our work has shown that inconsistencies in threat assessments occur because of ad hoc simulation and modeling methodologies, as well as dataset errors,' Sekar said. 'This shows the need for the creation of standardized public toolkits and datasets and for recommending ways to increase the accuracy of evaluations. This will enable us, as well as other researchers, to develop more rigorous foundations for securing tomorrow's electric energy grid.' Policy that meets the moment CMU's expertise extends beyond the labs and code to shape public policy through systems modeling, data-driven decision making and collaboration with government and industry. Ramayya Krishnan, director of the AI Measurement Science and Engineering Center, has said CMU's ability to look at issues from a systems standpoint is what makes the university uniquely positioned to address the complex challenges and opportunities that lie at the intersection of energy and AI. "That's our sweet spot," Krishnan said. "At CMU, we have strength in all the different layers. We have deep expertise in energy, deep expertise in AI and deep expertise in public policy, and we understand how these elements come together." Carnegie Mellon University brings together experts across disciplines to address real-world challenges and create lasting impact. From advancing technology to improving lives, CMU is committed to research, innovation, and education that drives meaningful change in society, industry, and communities around the world.

GLP-1 RAs Protective Against Stroke, Neurodegeneration?
GLP-1 RAs Protective Against Stroke, Neurodegeneration?

Medscape

time26 minutes ago

  • Medscape

GLP-1 RAs Protective Against Stroke, Neurodegeneration?

TOPLINE: Use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs), particularly semaglutide and tirzepatide, was associated with a 37% reduced risk for dementia and a 19% reduced risk for ischemic stroke in adults with type 2 diabetes (T2D) and obesity compared to the use of other antidiabetic drugs in a new retrospective cohort study. The neuroprotective effects of GLP-1 RAs were more pronounced in older adults, women, and those with a BMI of 30-40. METHODOLOGY: Investigators analyzed data on more than 60,000 adults aged 40 years or older with T2D and obesity and without type 1 diabetes or preexisting neurodegenerative or cerebrovascular diseases, obtained from electronic health records between 2017 and 2024. After propensity-score matching, participants receiving semaglutide or tirzepatide were assigned to the GLP-1 RA group (n = 30,430; mean age, 58 years; 50% women; 56% White individuals), and those receiving biguanides, sulfonylureas, alpha-glucosidase inhibitors, thiazolidinediones, dipeptidyl peptidase 4 inhibitors, and SGLT2 inhibitors were assigned to the 'other antidiabetic drug' group (n = 30,430; mean age, 58 years; 51% women; 56% White individuals). Primary outcomes were the incidence of new‐onset neurodegenerative diseases (dementia, Parkinson's disease, and mild cognitive impairment) and cerebrovascular diseases (ischemic stroke and intracerebral hemorrhage). The secondary outcome was all-cause mortality. TAKEAWAY: Patients taking GLP-1 RAs had a significantly lower risk for dementia (hazard ratio [HR], 0.63), ischemic stroke (HR, 0.81), and all-cause mortality (HR, 0.70) than those taking other antidiabetic drugs. Compared with use of other antidiabetic drugs, use of semaglutide was associated with reduced risk for dementia (HR, 0.63), whereas use of tirzepatide was associated with reduced risk for stroke (HR, 0.69) and all-cause mortality (HR, 0.48). No significant differences in risk for Parkinson's disease or intracerebral hemorrhage were observed between the GLP-1 RA group and the other antidiabetic group. The neuroprotective effects of GLP-1 RAs were more pronounced in women (HR, 0.85), adults aged 60 years or older (HR, 0.85), White individuals (HR, 0.86), and those with a BMI of 30-40 (HR, 0.82). IN PRACTICE: 'These findings suggest that semaglutide and tirzepatide may offer neuroprotective and cerebrovascular benefits beyond glycemic control, potentially improving long-term cognitive and survival outcomes in adults with T2D and obesity,' the investigators wrote. 'If shown to be protective for neurodegenerative diseases in future trials, GLP-1 RAs could potentially be used clinically in disease prevention in the future,' Sarah Marzi, PhD, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, England, said in an online comment. Marzi was not involved with the current research. SOURCE: The study was led by Huan-Tang Lin, MD, PhD, Chang Gung Memorial Hospital, Taoyuan, Taiwan. It was published online on July 15 in JAMA Network Open. LIMITATIONS: As an observational study, residual confounding from unmeasured factors such as frailty or functional status could not be excluded, potentially introducing healthy user or selection bias. The database used lacked biomarker data, genetic profiles, and neuroimaging assessments, limiting further mechanistic interpretations. The analysis did not account for death as a competing risk. Additionally, medication exposure was inferred from prescriptions without confirmation of actual adherence or accurate drug doses. DISCLOSURES: The study was funded by the Ministry of Science and Technology, Taiwan, and the Chang Gung Memorial Hospital. The investigators reported having no relevant conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store